Latest news
Tonix Gets FDA Alignment on TNX-4800 Phase 2 Lyme Disease Study Design - The Clinical Trial VanguardThe Clinical Trial Vanguard · Wed, 05 Aug 2026 06:33:35 GMTAlessa Therapeutics Receives Positive FDA Feedback Following Type - The National Law ReviewThe National Law Review · Tue, 04 Aug 2026 01:05:00 GMTAcurx's ~550-Patient Trial Could Support C. diff Treatment, Recurrence Reduction - Stock TitanStock Titan · Mon, 03 Aug 2026 12:00:00 GMTTonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. - Yahoo FinanceYahoo Finance · Mon, 03 Aug 2026 11:00:00 GMTGlucotrack advances LT-100 toward single-injection dosing after FDA Type C meeting and minipig study - TradingViewTradingView · Thu, 30 Jul 2026 21:33:01 GMT